Amyris Commissions Commercial Production Operations at Antibióticos

Expands Amyris Production Capacity to Two Commercial Facilities on Two Continents

EMERYVILLE, Calif.--()--Amyris, Inc. (NASDAQ:AMRS) announced the commissioning of its second industrial-scale facility for the production of Biofene™, Amyris’s renewable farnesene. The production facility is located in León, Spain at a facility owned by Antibióticos, S.A. Amyris is currently producing Biofene using Amyris equipment at a facility owned by Biomin do Brasil Nutricão Animal Ltda. in Piracicaba, Brazil.

Amyris plans to sell Biofene directly for use in industrial applications or to apply simple chemical finishing steps to Biofene to form a broad range of renewable products including squalane, base oil and finished lubricants and diesel.

“We are pleased to ramp up Biofene volume with our second commercial production facility,” said John Melo, CEO of Amyris. “We are seeing strong customer demand for squalane and our renewable diesel, and this increase in production also supports our expected near-term commercialization of Amyris base oils.”

Amyris is scaling its production through agreements with manufacturers located in Brazil, Europe and the United States, and has five production agreements in place including contract manufacturing agreements with Antibióticos, Biomin, Paraíso Bioenergia Ltda., Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC, and a joint venture with Usina São Martinho, one of the largest sugar and ethanol producers in Brazil. Amyris has also established chemical finishing capabilities under a production agreement with Glycotech, Inc.

About Amyris, Inc.

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda, a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels, LLC. More information about Amyris is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding commercial-scale production and commercialization and anticipated benefits of our products) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on March 14, 2011 and quarterly report on Form 10-Q filed on May 11. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

Contacts

Schwartz Communications
Merrill Freund or Alison Mickey, 415-512-0770 (Press)
amyris@schwartzcomm.com

Release Summary

Amyris, Inc. (NASDAQ: AMRS) announced the commissioning of its second industrial-scale facility for the production of Biofene™, Amyris’s renewable farnesene.

Contacts

Schwartz Communications
Merrill Freund or Alison Mickey, 415-512-0770 (Press)
amyris@schwartzcomm.com